Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Our Experiences by 2016

61 views

Published on

  • Be the first to comment

  • Be the first to like this

Our Experiences by 2016

  1. 1. “Spectrum” of Services
  2. 2. Oncology Experience Indication Imaging Modalities # ofStudies # ofPatientsPh I Ph II Ph III Ph IV BladderCancer CT, MRI, XR, Bone 2 1 1,100 Breastcancer CT, MRI, XR 1 4 7 3,600 ChronicLymphocyticLeukemia CT, MRI, PET 2 2 4 1,500 Colon CT, MRI, PET 3 1 2,200 Colorectal CT, MRI, PET 3 2 700 Diffuse Large B-Cell Lymphoma CT, MRI, PET 2 1 500 Esophagus CT, MRI, PET 1 200 FollicularLymphoma CT, MRI, PET 2 700 Gastric Cancer CT 1 3 2,300 HCC CT, MRI 3 1 800 Head& Neck CT, MRI, PET 3 1 340 Mantle Cell Lymphoma CT, MRI, PET 1 2 320 Melanoma CT, MRI, PET 2 3 4 3,800 Multiple Myeloma MRI 1 70 Non-HodgkinsLymphoma CT, MRI, PET 1 6 7 3,900 Non-Small Cell LungCancer CT, MRI, XR, Bone 3 8 3,600 Ovarian CT, MRI 3 4 2,600 Pancreatic CT, MRI, XR 1 3 1 1,400 Prostate Cancer CT, MRI, XR, Bone 1 5 6 7,000 RCC MRI, PET 1 1 900 Sarcoma CT, MRI 1 1 500 SolidTumors CT, MRI 2 75
  3. 3. Other Therapeutic Areas CNS Phases # ofsites # ofpatients Modalities Multiple Sclerosis II,III 40-160 10-1,500 MR SubarachnoidHemorrhage III 100-150 750-1,500 CT, DSA,CTA MSK Phases # ofsites # ofpatients Modalities Osteoporosis I, II,III 1-400 12-17,000 X-Ray,DXA RheumatoidArthritis I, II,III 1-80 10-1,500 X-Ray,MRI Osteoarthritis I, II,III 1-350 12-2,250 X-Ray,MRI Cardiology Phases # ofsites # ofpatients Modalities Peripheral Arterial Occlusion III 90 100 Arteriograms Fabry Disease II,III 2 60 Echo Heart Failure III 40 600 Echo Atrial Fibrillation Pivotal Device 25 220 CTA,TEE, CT, MR EisenmengerSyndrome III 90 220 PA,CTPA,MRA, Echo Pulmonary Phases # ofsites # ofpatients Modalities Arterial Hypertension IV 30 100 PET, cMRI, 3D Echo ChronicThromboembolicHypertension II 60 150 PA,CTPA,MRA, V/Q Imaging Agents Phases # ofsites # ofpatients Modalities Vascular III 15-25 35-300 MRA, DSA Renal III 25 330 MRI Oncology I, III 1 30-140 CT, PET-CT,SPECT-CT
  4. 4. Immunotherapy Experience Phase Indication Agent Type Criteria Endpoint # of sites # of subjects III NSCLC Vaccine therapy RECIST 1.1 ProgressionFree Survival (PFS) 89 506 III Non-Hodgkin’s Lymphoma Autologoustumorderived immunoglobulinidiotypevaccine Cheson Disease Free Survival (DFS) 30 650 III MetastaticMelanoma Oncolyticviral vaccine therapy ModifiedirRC Durable Response Rate 75 400 II MetastaticMelanoma Monoclonal antibody irRC & RECIST 1.1 PFS 31 100 I Hepatocellular Carcinoma Intralesionalinjection RECIST 1.1 PFS 2 45 III Colon Autologoustumorcell immunotherapy RECIST 1.1 DFS 40 550 II Ovarian Autologoustumorcell immunotherapy RECIST 1.1 Recurrence-FreeSurvival 80 400 III LocallyAdvanced CutaneousMelanoma Intralesionalinjection RECIST 1.1 PFS 30 225 III MetastaticMelanoma Oncolyticviral vaccine therapy/anti-PD-1monoclonal antibody Modified irRECIST& RECIST PFS 150 800

×